PMID- 34349464
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210806
IS  - 0973-6247 (Print)
IS  - 1998-3565 (Electronic)
IS  - 0973-6247 (Linking)
VI  - 15
IP  - 1
DP  - 2021 Jan-Jun
TI  - Extent of transfusion support in a developing country in managing a bleeding 
      acute myeloid leukemia patient with platelet transfusion refractoriness.
PG  - 90-93
LID - 10.4103/ajts.AJTS_81_19 [doi]
AB  - Conventional platelet transfusion may not be adequate to deal with platelet 
      transfusion refractoriness (PTR), and therefore human leukocyte antigen (HLA) or 
      human platelet antigen (HPA) matched and platelet crossmatch compatible units are 
      recommended. However, in developing countries, finding a unit that is HLA or HPA 
      matched or platelet crossmatch poses a challenge. Hence, easier and 
      cost-effective alternatives such as massive platelet transfusion and continuous 
      platelet transfusion were attempted to manage bleeding in PTR. A 31-year-old male 
      presented with acute myeloid leukemia relapse and chloroma in bladder underwent 
      FLAG salvage chemotherapy. Despite almost daily platelet transfusion with single 
      donor platelets (SDPs), patient presented with hematuria and low corrected count 
      increment at 1 h and 24 h suggesting both immune and nonimmune refractoriness to 
      platelet transfusion. The patient received SDP transfusion twice daily from day 
      19 to day 21 to maintain hemostasis. The patient had persistent hematuria, so 
      massive platelet transfusion in the form of double adult doses of SDP given every 
      12(th) hourly for three events. Despite these measures, there was persistent 
      hematuria and refractoriness to platelet transfusion. As HLA or HPA matched or 
      crossmatch compatible platelets were unavailable, continuous platelet transfusion 
      was started for this patient from day 23 to day 28. After 4 days of continuous 
      platelet transfusion, hematuria subsided. In resource-constrained clinical 
      settings, continuous platelet transfusion can be an effective alternative to 
      HLA/HPA-matched platelets in the management of PTR.
CI  - Copyright: (c) 2021 Asian Journal of Transfusion Science.
FAU - Chellaiya, Gayathiri K
AU  - Chellaiya GK
AD  - Department of Transfusion Medicine, Malabar Cancer Centre, Thalassery, Kerala, 
      India.
FAU - Nair, Chandran K
AU  - Nair CK
AD  - Department of Clinical Hematology, Malabar Cancer Centre, Thalassery, Kerala, 
      India.
FAU - Raghavan, Vineetha
AU  - Raghavan V
AD  - Department of Clinical Hematology, Malabar Cancer Centre, Thalassery, Kerala, 
      India.
FAU - Pandian, R Jesu
AU  - Pandian RJ
AD  - Department of Clinical Hematology, Malabar Cancer Centre, Thalassery, Kerala, 
      India.
FAU - Vinod, Roshan
AU  - Vinod R
AD  - Department of Clinical Hematology, Malabar Cancer Centre, Thalassery, Kerala, 
      India.
FAU - Murugesan, Mohandoss
AU  - Murugesan M
AD  - Department of Transfusion Medicine, Malabar Cancer Centre, Thalassery, Kerala, 
      India.
LA  - eng
PT  - Case Reports
DEP - 20210612
PL  - India
TA  - Asian J Transfus Sci
JT  - Asian journal of transfusion science
JID - 101306858
PMC - PMC8294443
OTO - NOTNLM
OT  - Continuous platelet transfusion
OT  - corrected count increment
OT  - massive platelet transfusion
OT  - platelet transfusion refractoriness
COIS- There are no conflicts of interest.
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
PMCR- 2021/01/01
CRDT- 2021/08/05 06:21
PHST- 2019/08/09 00:00 [received]
PHST- 2020/12/13 00:00 [accepted]
PHST- 2021/08/05 06:21 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - AJTS-15-90 [pii]
AID - 10.4103/ajts.AJTS_81_19 [doi]
PST - ppublish
SO  - Asian J Transfus Sci. 2021 Jan-Jun;15(1):90-93. doi: 10.4103/ajts.AJTS_81_19. 
      Epub 2021 Jun 12.